A randomized, open label, cross-over comparative study of irbesartan/hydrochlorothiazide and irbesartan in the treatment of mild to moderate hypertension.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Irbesartan/hydrochlorothiazide (Primary) ; Irbesartan
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 06 Nov 2008 Actual patient number (60) added as reported by ClinicalTrials.gov.
- 06 Nov 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 06 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.